RE:RE:New PR aroundVM "These new findings also indicate that both peptide-drug conjugates, in addition to their reported cytotoxicity, could possibly inhibit VM in SORT1-positive TNBC and ovarian cancer patients."
Seems to me that's a clear statement they are putting forward a second MOA for the drug that is distinct from the cytotoxicity of the chemo drug attached. They are now clearly linking that to inhibition/interference with SORT1.
So maybe you can take Wino's fun logic from earlier around efficacy and add another roll of the dice to say if Wino's narrowing of the possible outcomes based on what we know doesn't result in a clear efficacy signal then MAYBE this does. Obviously we don't know if this new MOA can produce a detectable efficacy signal in patients but it seems to me at least to be another free roll of the dice.